Definition In 2003 Eli Lilly and Company offered a more precise definition of<unk>  when the pharmaceutical company submitted clinical trial data to the U.S. Food and Drug Administration (FDA) requesting approval to advertise their brand of growth hormone for the treatment of<unk> . They proposed a definition of a height more than 2.25 standard deviations below mean, roughly equal to the shortest 1.2% of the population. Other researchers have described a cutoff of 2.0 standard deviations.
Idiopathic short stature
Psychosocial short stature
Constitutional growth delay
Congenital adrenal hyperplasia
Hypothyroidism
Isolated growth hormone deficiency
Micromegaly
Late onset congenital adrenal hyperplasia